Apomorphine in the treatment of Parkinson's disease

Bibliography

• PAHWA R, LYONS KE: Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review. Neurol. Clin. (2004) 22(Suppl. 3):S35-S52.
   Google Scholar
• SWOPE DM: Rapid treatment of “wearing off” in Parkinson's disease. Neurology (2004) 62(Suppl. 4):S27-S31.
   PubMed Web of Science ®Google Scholar
• MATTHEISSEN A, WRIGHT CR: Research into the chemical constitution of the opium bases. Part 1: on the action of hydrochloric acid on morphia. Proc. R. Soc. Lond. B. Biol. Sci. (1869) 17:455-460.
   Google Scholar
• ZURICH FM: Apomorphine. The formation of apomorphine on heating and preserving morphine solutions. Z. Physiol. Chem. (1913) 84:363-378.
   Google Scholar
• WEIL E: De l'apomorphine dans certain troubles nerveux. Lyon. Med. (1884) 48:411-419.
   Google Scholar
• SCHWAB RS, AMADOR LV, LETTVIN JY: Apomorphine in Parkinson's disease. Trans. Am. Neurol. Assoc. (1951) 56:251-253.
   PubMedGoogle Scholar
• COTZIAS GC, PAPAVASILIOU PS, FEHLING C et al.: Similarities between neurologic effects of L-Dopa and of apomorphine: N. Engl. J. Med. (1970) 282:31-33.
   PubMed Web of Science ®Google Scholar
• ERNST AM: Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia (1967) 10:316-323.
   PubMed Web of Science ®Google Scholar
• ANDEN NE, RUBENSON A, FUXE K, HOKFELT T: Evidence of dopamine receptor stimulation by apomorphine. J. Pharm. Pharmacol. (1967) 19:627-629.
   PubMed Web of Science ®Google Scholar
• CASTAIGNE P, LAPLANE D, DORDAIN G: Clinical experimentation with apomorphine in Parkinson's disease. Res. Commun. Chem. Pathol. Pharmacol. (1971) 2(2):154-158.
   PubMedGoogle Scholar
• COTZIAS GC, PAPAVASILIOU PS, TOLOSA ES, MENDEZ JS, BELL-MIDURA M: Treatment of Parkinson's disease with apomorphines: possible role of growth hormones. N. Engl. J. Med. (1976) 295:567-572.
   Google Scholar
• KLEIN RL, MILITELLO TE, BALLINGER CM: Antiemetic effect of metoclopramide. Evaluation in humans. Anesth. Analg. (1968) 47:259-264.
   PubMed Web of Science ®Google Scholar
• GYLDING-SABROE JP, HATTEL T: Metoclopramide. A new quick acting antiemetic. Nord. Med. (1969) 81:141-142.
   PubMedGoogle Scholar
• CORSINI GU, GESSA GL, DEL ZOMPO M, MANGONI A: Therapeutic efficacy of apomorphine combined with extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet (1979) 1:954-956.
   PubMed Web of Science ®Google Scholar
• STIBE CM, KEMPSTER PA, LEES AJ, STERN GM: Subcutaneous apomorphine in Parkinsonian on-off oscillations. Lancet (1988) 1:403-406.
   PubMed Web of Science ®Google Scholar
• OSTERGAARD L, WERDELIN L, ODIN P: Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind placebo controlled study. J. Neurol. Neurosurg. Psychiatry (1995) 58:681-687.
   PubMed Web of Science ®Google Scholar
• MERELLO M, PIKIELNY R, CAMMAROTA A, LEIGUARDA R: Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double blind placebo controlled study. Clin. Neuropharmacol. (1997) 20:165-167.
   PubMed Web of Science ®Google Scholar
• DEWEY RB Jr, HUTTON JT, LEWITT PA, FACTOR SA: A randomized, double-blinded, placebo-controlled trial of subcutaneous injected apomorphine for parkinsonian off-state events. Arch. Neurol. (2001) 58(9):1385-1392.
   PubMed Web of Science ®Google Scholar
• HUTCHINSON WD, LEVY R, DOSTROVSKY JO, LOZANO AM, LANG AE: Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann. Neurol. (1997) 42(5):767-775.
   PubMed Web of Science ®Google Scholar
• NEUMEYER JL, BALDESSARINI RJ, ARANA GW, CAMPBELL A: Aporphines as dopamine receptor agonists and antagonists at central dopamine receptors. New Methods Drug Res. (1985) 1:153-166.
   Google Scholar
• FACTOR SA: Dopamine agonists. Med. Clin. North Am. (1999) 83(2):415-443.
   PubMed Web of Science ®Google Scholar
• DUBY SE, COTZIASGC, PAPAVASILIOU PS, LAWRENCE WH: Injected apomorphine and orally administered levodopa in Parkinsonism. Arch. Neurol. (1972) 27(6):474-480.
   PubMedGoogle Scholar
• SHERRY JH GP, VAN LUNEN B, BOTTINI PB: Continued efficacy and safety of subcutaneous injections of apomorphine in the treatment of “off” episodes in patients with Parkinson's disease. Neurology (2003) 60(Suppl. 1):A81.
   Google Scholar
• NEWMAN-TACREDI A, CUSSAC et al.: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of Dopamine D2-like receptors and α1/α2-adrenoceptor. J. Pharmacol. Exp. Ther. (2002) 303:805-814.
   PubMed Web of Science ®Google Scholar
• MILLAN MJ, MAIOFUSS L, CUSSAC D et al.: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. (2002) 303:791-804.
   PubMed Web of Science ®Google Scholar
• NEWMAN-TACREDI A, CUSSAC et al.: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1,and 5-HT2 receptor subtypes. J. Pharmacol. Exp. Ther. (2002) 303:815-822.
   PubMed Web of Science ®Google Scholar
• ZHANG AO, ZHANG Y, BRANFMAN AR, BALDESSARINI RJ, NEUMEYER JL: Advances in the development of doapminergic aporphinoids. J. Med. Chem. (2007) 50(2):171-181.
   PubMed Web of Science ®Google Scholar
• GASSEN M,GROSS A, YOUDIM MBH: Apomorphine enantiomers protect cultured phenochromocytoma(PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov. Disord. (1998) 13(2):242-248.
   PubMed Web of Science ®Google Scholar
• GRUNBLATT E, MANDEL S, BERKUZKI T, YOUDIM MBH: Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. (1999) 14(4):612-618.
   PubMed Web of Science ®Google Scholar
• KUNO S, OHTA M, OTHA K, MIZUTA I: Expression of neurotrophic factors in cultured mouse astroglial cells by apomorphine. Mov. Dis. (2000) 15(Suppl. 3):23.
   Google Scholar
• GAUCHER ST, WOODWARD WR, BOUCHER B et al.: Peripheral pharmacokinetics of apomorphine in humans. Ann. Neurol. (1989) 26:232-238.
   PubMedGoogle Scholar
• NICOLLE E, POLLAK P, SERRE-DEBEAUVAIS F et al.: Pharmacokinetics of apomorphine in Parkinsonian patients. Fundam. Clin. Pharmacol. (1993) 7:245-252.
   PubMed Web of Science ®Google Scholar
• HARDER S, BAAS H, DEMISCH L, SIMON E: Dose response and concentration response relationship of patients with Parkinson's disease and end-of-dose akinesia. Int. J. Clin. Pharmacol. Ther. (1998) 36:355-362.
   PubMedGoogle Scholar
• HOFSTEE DJ, NEEF C, VAN LAAR, JANSEN EN: Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses. Clin. Neuropharmacol. (1994) 17:45-52.
   PubMed Web of Science ®Google Scholar
• NEEF C, VAN LAAR T: Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin. Pharmacokinet. (1999) 37:257-271.
   PubMed Web of Science ®Google Scholar
• KAUL PN, BROCHMAN-HANSSEN E, WAY EL: Biological disposition of apomorphine. Urinary excretion and organ distribution of apomorphine. J. Pharma. Sci. (1961) 50:244-247.
   PubMed Web of Science ®Google Scholar
• VAN DER GEEST R, KRUGER P, GUBBENS-STIBBE JM et al.: Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulphate conjugates in plasma and urine of patients with Parkinson's disease. J. Chromatogr. B (1997) 702:131-141.
   PubMed Web of Science ®Google Scholar
• VAN DER GEEST R, KRUGER PP et al.: Pharmacokinetics, enantiomer interconversion and metabolism of the R-apomorphine in patients with idiopathic Parkinson's disease. Clin. Neuropharmacol. (1998) 21:159-168.
   PubMed Web of Science ®Google Scholar
• VERHAGEN ML, LOCATELI ER, BRAVI D et al.: Apomorphine responses in Parkinson's disease and pathogenesis of motor complications. Neurology (1997) 48:369-372.
   PubMed Web of Science ®Google Scholar
• STACY M: Apomorphine North American clinical experience. Neurology (2004) 62(Suppl.):S18-S21.
   PubMed Web of Science ®Google Scholar
• PFEIFER RF, GUTMAN L, HULL KL et al.: Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat. Disord. (2007) 13(2):93-100.
   PubMed Web of Science ®Google Scholar
• TROSCH R: Decrease in UPDRS motor scores following intermittent subcutaneous apomorphine for 6 months in patients with advanced Parkinson's disease. Mov. Disord. (2004) 19(Suppl. 9):S217.
   PubMedGoogle Scholar
• HARDIE RJ, LEES AJ, STERN GM: On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain (1984) 107(2):487-506.
   PubMed Web of Science ®Google Scholar
• VAN LAAR T, JANSEN EN, ESSINK AW, NEEF C: A double-blind study of the efficacy of apomorphine and its assessment in “off”periods in Parkinson's disease. Clin. Neurol. Neurosurg. (1993) 95(3):231-235.
   PubMed Web of Science ®Google Scholar
• HUGHES AJ, BISHOP S, KLEEDORFER B et al.: Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov. Disord. (1993) 8(2):165-170.
   PubMed Web of Science ®Google Scholar
• DELEU D, NORTHWAY MG, HANSSENS Y: Clinical pharmacokinetics and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin. Pharmacominet. (2002) 41(4):261-309.
   Google Scholar
• DELEU D, HANSSENS Y, NORTHWAY MG: Subcutaneous apomorphine: an evidence based review of its use in Parkinson's disease. Drugs Aging (2004) 21:687-709.
   PubMed Web of Science ®Google Scholar
• BOWRON A: Practical considerations in the use of apomorphine injectable. Neurology (2004) 62(Suppl. 4):S32-S36.
   PubMed Web of Science ®Google Scholar
• LEES AJ, RICHARDSON C, TURNER K: Treatment of Parkinson's disease with apomorphine. Shared guidelines, 3rd Edition. UCL Hospitals, NHS trust (1998).
   Google Scholar
• PIETZ K, HAGELL P, ODIN P: Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J. Neurol. Neurosurg. Psychiatry (1998) 65(5):709-716.
   PubMed Web of Science ®Google Scholar
• HAGELL P, ODIN P: Apomorphine in the treatment of Parkinson's disease. J. Neurosci. Nursing (2001) 33(1):21-37.
   PubMedGoogle Scholar
• MANSON AJ, HANAGASI H, TURNER K et al.: Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observation. Brain (2001) 124:331-340.
   PubMed Web of Science ®Google Scholar
• ESTEBAN MUNOZ J, MARTI MJ, MARIN C, TOLOSA E: Long term treatment with intermittent intranasal or subcutaneous apomorphine in patients with levodopa-related motor fluctuations. Clin. Neuropharmacol. (1997) 20:245-252.
   PubMedGoogle Scholar
• KLEEDORFER B, TURJANSKI N, RYAN R et al.: Intranasal apomorphine in Parkinson's disease. Neurology (1991) 41:761-762.
   PubMed Web of Science ®Google Scholar
• DEWEY RB Jr, MARAGANORE DM, AHLSKOG JE, MATSUMOTO JY: Intranasal apomorphine rescue therapy for Parkinsonian “off” periods. Clin. Neuropharmacol. (1996) 19:193-201.
   PubMed Web of Science ®Google Scholar
• DEWEY RB Jr, MARAGANORE DM, AHLSKOG JE, MATSUMOTO JY: A double-blind placebo-controlled study of intranasal apomorphine as a rescue agent for off-states in Parkinson's disease. Mov. Disord. (1998) 13(5):782-787.
   PubMed Web of Science ®Google Scholar
• MONTASTRUC JL, RASCOL O, SENARD JM et al.: Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin. Neuropharmacol. (1991) 14:432-437.
   PubMed Web of Science ®Google Scholar
• DURIF F, DEFFOND D, DORDAIN G et al.: Apomorphine and diphasic dyskinesia. Clin. Neuropharmacol. (1994) 17:99-102.
   PubMed Web of Science ®Google Scholar
• ONDO W, HUNTER C, ALMAGUER M, JANKOVIC J: A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov. Disord. (1999) 14:664-668.
   PubMed Web of Science ®Google Scholar
• HUGHES AJ, WEBSTER R, BONINGDON M, LEES AJ, STERN GM: Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. Clin. Neuropharmacol. (1991) 14:556-561.
   PubMed Web of Science ®Google Scholar
• VAN LAAR T, JANSEN EN, NEEF C, DANHOF M, ROOS RA: Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov. Disord. (1995) 10:433-439.
   PubMed Web of Science ®Google Scholar
• HUGHES AJ, BISHOP S, LEES AJ, STERN GM, WEBSTER R, ROVINGTON M: Rectal apomorphine in Parkinson's disease. Lancet (1991) 337:118.
   PubMed Web of Science ®Google Scholar
• DODEL RC, BERGER K, OERTEL WH: Health related quality of life and healthcare utilization in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics (2001) 19:1013-1038.
   PubMed Web of Science ®Google Scholar
• SCHRAG A, QUINN N: Dyskinesias and motor fluctuations in Parkinson's disease: a community based study. Brain (2000) 123:2297-2305.
   PubMed Web of Science ®Google Scholar
• STACY M, BOWRON A, GUTTMAN M et al.: Identification of motor and non-motor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov. Disord. (2005) 20:726-733.
   PubMed Web of Science ®Google Scholar
• CARTER JH, STEWART BJ, ARCHBOLD PG et al.: Living with a person who had Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group. Mov. Dis. (1998) 113:20-28.
   Google Scholar
• DE GASPARI D, SIRI C, LANDI A et al.: Clinical and neurophysiological follow up at 12 months on patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatry (2006) 77:450-453.
   PubMed Web of Science ®Google Scholar
• KEMPSTER PA, FRANKEL JP, STERN GM, LEES AJ: Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry (1990) 53:1004-1007.
   PubMed Web of Science ®Google Scholar
• POLLAK P, CHAMPAY AS, HOMMEL M et al.: Subcutaneous apomorphine in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry (1989) 52:544.
   PubMed Web of Science ®Google Scholar
• POEWE W, KLEEDORFER B, GERSTENBRAND F, ORTEL W: Subcutaneous apomorphine in Parkinson's disease. Lancet (1988) 1:943.
   PubMedGoogle Scholar
• POEWE W, KLEEDORFER B, WAGNER M et al.: Side effects of subcutaneous apomorphine in Parkinson's disease. Lancet (1989) 1:1084-1085.
   PubMedGoogle Scholar
• FRANKEL JP, LEES AJ, KEMPSTER PA, STERN GM: Subcutaneous apomorphine in the treatment of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry (1990) 53:96-101.
   PubMed Web of Science ®Google Scholar
• HUGHES AJ, LEES AJ, STERN GM: The motor response to sequential apomorphine in parkinsonian fluctuations. J. Neurol. Neurosurg. Psychiatry (1991) 54:358-360.
   PubMed Web of Science ®Google Scholar
• HUGHES AJ, BISHOP S, STERN GM, LEES AJ: The motor response to repeated apomorphine administration in Parkinson's disease. Clin. Neuropharmacol. (1991) 14:209-213.
   PubMed Web of Science ®Google Scholar
• DEFFOND D, DURIF F, TOURNILHAC M: Apomorphine in the treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes. J. Neurol. Neurosurg. Psychiatry (1993) 56:101-103.
   PubMed Web of Science ®Google Scholar
• GERVASON CL, POLLAK PR, LIMOUSIN P, PERRET JE: Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease. Clin. Neuropharmacol. (1993) 16:113-119.
   PubMed Web of Science ®Google Scholar